Attarian S, Fatehi F, Rajabally Y A, et al. Hereditary neuropathy with liability to pressure palsies [J]. J Neurol, 2020, 267(8): 2198-2206.
[2]
Paassen B W, Kooi A J, Spaendonck K Y, et al. PMP22 related neuropathies: charcot-marie-tooth disease type 1A and hereditary neuropathy with liability to pressure palsies [J]. Orphanet J Rare Dis, 2014, 9: 38.
Guo J, Wang L, Zhang Y, et al. Abnormal junctions and permeability of myelin in PMP22-deficient nerves [J]. Ann Neurol, 2014, 75(2): 255-265.
[5]
Robert V F, Jousserand G, Bouhour F, et al. Hereditary neuropathy with liability to pressure palsy in patients under 30 years old: neurophysiological data and proposed electrodiagnostic criteria [J]. Muscle Nerve, 2018, 57(2): 217-221.
Blomqvist M, Zetterberg H, Blennow K, et al. Sulfatide in health and disease. the evaluation of sulfatide in cerebrospinal fluid as a possible biomarker for neurodegeneration [J]. Mol Cell Neurosci,2021, 116:103670.
[8]
Moriguchi K, Nakamura Y, Park A M, et al. Anti-glycolipid antibody examination in five EAE models and theiler’s virus model of multiple sclerosis: detection of anti-GM1, GM3, GM4, and sulfatide antibodies in relapsing-remitting EAE [J]. Int J Mol Sci, 2023, 24(16): 12937.
[9]
Sun R, Meng Y, Li L, et al. A rare presentation of acute-onset chronic inflammatory demyelinating polyneuropathy with the detection of anti-GM3 and anti-sulfatides antibodies: a case report [J]. Front Immunol, 2024, 15: 1409637.
[10]
Kleiser B, Giesche N, Kowarik M C, et al. Anti-sulfatide antibodies in neurological disorders: should we test? [J]. J Neurol, 2024, 271(12):7613-7618.
Chen L, Zhang H, Li C, et al. Literature review of clinical analysis of hereditary neuropathy with liability to pressure palsies [J]. J Neurol,2024, 272(1):41.
[13]
Moss K R, Bopp T S, Johnson A E, et al. New evidence for secondary axonal degeneration in demyelinating neuropathies [J]. Neurosci Lett,2021, 744:135595.
2025, Vol. 36 
